Tokiwa Pharmaceutical Develops Atypical Dermatitis Diagnostic Kit
This article was originally published in PharmAsia News
Executive Summary
Tokiwa Pharmaceutical and Shimane University jointly developed a new testing kit using fluorescence detection of the TARC protein to diagnosis the severity atopic dermatitis. The team found that patients with atypical dermatitis have significantly higher TARC levels and the level of seriousness corresponds to the TARC level. (Click here for more - Japanese language